- Home
- IMTX vs DVAX Comparison
IMTX vs DVAX Comparison
Compare IMTX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- DVAX
- Stock Information
- Founded
- IMTX N/A
- DVAX 1996
- Country
- IMTX Germany
- DVAX United States
- Employees
- IMTX N/A
- DVAX N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- DVAX Health Care
- Exchange
- IMTX Nasdaq
- DVAX Nasdaq
- Market Cap
- IMTX 1.1B
- DVAX 1.2B
- IPO Year
- IMTX N/A
- DVAX 2004
- Fundamental
- Price
- IMTX $10.25
- DVAX $11.08
- Analyst Decision
- IMTX Strong Buy
- DVAX Buy
- Analyst Count
- IMTX 4
- DVAX 4
- Target Price
- IMTX $13.67
- DVAX $26.50
- AVG Volume (30 Days)
- IMTX 654.5K
- DVAX 1.7M
- Earning Date
- IMTX 11-14-2025
- DVAX 11-05-2025
- Dividend Yield
- IMTX N/A
- DVAX N/A
- EPS Growth
- IMTX N/A
- DVAX N/A
- EPS
- IMTX N/A
- DVAX N/A
- Revenue
- IMTX $152,823,253.00
- DVAX $330,514,000.00
- Revenue This Year
- IMTX N/A
- DVAX $23.23
- Revenue Next Year
- IMTX $13.52
- DVAX $16.57
- P/E Ratio
- IMTX N/A
- DVAX N/A
- Revenue Growth
- IMTX 83.61
- DVAX 26.73
- 52 Week Low
- IMTX $3.30
- DVAX $9.20
- 52 Week High
- IMTX $11.25
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- IMTX 56.67
- DVAX 61.75
- Support Level
- IMTX $8.92
- DVAX $9.92
- Resistance Level
- IMTX $10.86
- DVAX $11.43
- Average True Range (ATR)
- IMTX 0.63
- DVAX 0.35
- MACD
- IMTX -0.05
- DVAX 0.08
- Stochastic Oscillator
- IMTX 71.66
- DVAX 75.83
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.